Listen on the go
CORRECT!
Next question
touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
Fungal Infections
Watch Time: 2 mins

Martin Hoenigl, IDWeek 2022: Candidemia prognosis and unmet needs in its treatment

Share this Video
Copy Link
Published Online: Nov 3rd 2022

Candidemia is the one of the most common form of invasive candidiasis, and in some countries the most common causes of bloodstream infections in hospitalized patients. In this touchINFECTIOUS DISEASES interview, we met with Dr Martin Hoenigl (Medical University of Graz, Austria) to discuss the prognosis of candidemia, the unmet needs in its treatment, and current recommended treatments.

Interviews available in this series:

Candidemia prognosis and unmet needs in its treatment

Guideline adherence predicts outcomes of candidemia in Europe

Questions:

  1. Could you tell us a little about candidemia, its prognosis and the unmet needs in its treatment?
  2. What is the recommended treatment for candidemia?

Disclosures: Martin Hoenigl is a consultant for Scynexis, Pulmocide, Gilead, Euro Pharma Holings, and Mundipharma; receives grant/research support from Gilead, Scynexis, Pfizer, MSD, Euroimun, and Mundipharma; and is on the advisory board for F2G.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of IDWeek 2022

Related Videos In Fungal Infections
Fungal Infections
Developed by Touch
Ibrexafungerp against Mucor strains using time-kill and scanning electron microscopy: ECCMID 2023, Mahmoud Ghannoum
Watch Time: 4 mins

Vulnerable immunocompromised individuals are at risk of opportunistic infections by invasive molds, and available antifungal treatments for these invasive infections are currently restricted. Therefore, a combination of therapies has been proposed as a potential strategy to enhance the effectiveness of treatment outcomes. Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals Cleveland Medical Centre, […]

Fungal Infections
Developed by Touch
Antifungal resistance – biofilms, tolerance phenomena, treatment and diagnostics: Mahmoud Ghannoum, ECCMID, 2023
Watch Time: 4 mins

Antifungal resistance is an increasing concern in the treatment of fungal infections, especially when there are already limited options in the treatment paradigm. It was a pleasure to talk with Editorial Board member Prof. Mahmoud Ghannoum (Integrated Microbiome Core and Center for Medical Mycology, Cleveland, OH, USA) around the impact of biofilms on antifungal therapy, […]

Fungal Infections
Developed by Touch
ECCMID 2023 highlights in fungal infections – diagnostics, treatments and case reports: Mahmoud Ghannoum
Watch Time: 2 mins

Editorial Board member Prof. Mahmoud Ghannoum (Integrated Microbiome Core and Centre for Medical Mycology, Cleveland, OH, USA) joins us to discuss ECCMID 2023 highlights in fungal infections, antifungal therapies, diagnostic approaches, and specific case reports that help advise clinicians in clinical practice. Interviews in this series: Ibrexafungerp against Mucor strains using time-kill and scanning electron […]

Trending In Fungal Infections:

Ibrexafungerp against Mucor strains using time-kill and scanning electron microscopy: ECCMID 2023, Mahmoud Ghannoum
Fungal Infections
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72